search
Back to results

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Primary Purpose

Metastatic Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK)
N803
Apheresis collection of lymphocytes (part A)
Sponsored by
ImmunityBio, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metastatic Solid Tumor

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  • Have histologically confirmed unresectable, locally advanced or metastatic solid tumor.
  • For subjects with genetic mutations or alterations in solid tumors (e.g. NSCLC, pancreatic cancer, melanoma), the subjects must have received prior appropriate disease specific targeted therapy and have progressed.
  • For subjects with a history of HIV
  • Subjects with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL and without a history of AIDS defining opportunistic infections are eligible.
  • For subjects with a history of HBV
  • Subjects who are chronic carriers of HBV infection (HBsAg-positive, undetectable or low HBV DNA, and normal ALT) who are not on HBV therapy, or in individuals who have serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and anti-HBc-positive), anti-HBV prophylaxis should be assessed prior to enrollment.
  • Subjects with chronic HBV infection with active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy prior to enrollment.
  • For subjects with a history of HCV
  • Subjects with a history of HCV infection should have completed curative antiviral treatment and have a HCV viral load below the limit of quantification are eligible.
  • Subjects who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible.
  • Subjects on concurrent HCV treatment and have HCV below the limit of quantification are eligible.

Note: Subjects who have a history of HIV/HBV/HCV or are seropositive will require Infectious Disease Marker (IDM) testing prior to apheresis collection.

  • Subjects with previously treated and who currently have non-progressive brain metastasis may participate in this study.
  • Able to undergo an Apheresis procedure:
  • Has adequate venous access
  • Able to sit or recline for 5-6 hours with limited movement
  • Hemoglobin must be ≥ 9.0 g/dL
  • Platelet count must be ≥ 100 cells/mm3
  • Vital signs must be within normal range
  • Negative pregnancy test for females of childbearing potential.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

Cohort 2 subjects only:

  • Have received treatment with at least 2 prior lines of therapy in the metastatic setting or not be a candidate for therapy of proven efficacy for their disease. Prior immune therapy and prior treatment with a checkpoint inhibitor as per FDA indication for current standard of care therapy is allowed.
  • Have at least 1 measurable lesion and/or non-measurable disease evaluable in accordance with RECIST Version 1.1.
  • Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  • Agreement to practice effective contraception for female subjects of child-bearing potential and nonsterile males.

Exclusion Criteria:

Cohort 2 subjects only:

  • Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment- related complications.
  • Currently receiving antibiotics for a recent infection.
  • Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma) requiring medical treatment
  • History of organ transplant requiring immunosuppression.
  • History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), unless the inflammation is well controlled.
  • Inadequate organ function, evidenced by the following laboratory results:
  • Absolute neutrophil count (ANC) < 1500 cells/mm3.
  • Platelet count < 100,000 cells/mm3.
  • Hemoglobin < 9 g/dL.
  • Total bilirubin greater than 1.5 x the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
  • Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
  • Alkaline phosphatase (ALP) levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
  • Serum creatinine > 2.0 mg/dL or 177 μmol/L.

Note: Each site should use its own institution's upper limit of normal (ULN) to determine eligibility.

  • For subjects who have received approved chemotherapy or approved immunotherapy, a repeat CBC a least 14 days after completion of the treatment to demonstrate recovery of counts to an ANC ≥1000 and Platelets ≥100,000 is required.
  • For subjects who have received investigational chemotherapy or investigational immunotherapy, a repeat CBC a least 30 days after completion of the treatment to demonstrate recovery of counts to an ANC ≥ 1000 and Platelets ≥ 100,000 is required.
  • Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.
  • Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. Oxygen therapy on an as needed or intermittent basis is allowed.
  • Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  • Known hypersensitivity to any component of the study medication(s).
  • Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  • Concurrent participation in any interventional clinical trial.
  • Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 72 hours prior to the first dose must be documented before M-CENK is administered to a female subject of childbearing potential.

Sites / Locations

  • Chan Soon-Shiong Institute for MedicineRecruiting
  • Hoag Memorial Hospital Presbyterian

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment

Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors

Arm Description

Cohort 1: Subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment. Cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy and meet the inclusion criteria for cohort 2 part B.

Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies or not a candidate for therapy of proven efficacy for their disease.

Outcomes

Primary Outcome Measures

Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.
- Safety of apheresis collection as indicated by incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, or in the case of cytokine release syndrome (CRS), using the specified grading system.
Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests.
- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to apheresis collection. Hematology test will be performed pre- and post- apheresis collection.
Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs.
- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation
Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (treatment cycle 1, Day 1)
- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using the specified grading system.
Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests
- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to first dose.
Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs
- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation

Secondary Outcome Measures

Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs for manufacturing M-CENK cells.
- Number of MNCs for manufacturing M-CENK cells
Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs collected and the % of natural killer (NK) cells.
Number of MNCs collected and the percentage of natural killer (NK) cells (CD56/CD16 positive) after a 2 blood volume apheresis collection.
Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells.
- Number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells as measured by flow cytometry and interferon (IFN) γ production, and cytotoxicity following enrichment and expansion of the NK cells ex vivo.
Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of cryopreserved aliquots of manufactured M-CENK cells.
- Number of cryopreserved aliquots of manufactured M-CENK cells.
Secondary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of up to 10 treatment cycles of M CENK and N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of TEAEs and SAEs.
- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using a specified grading system.
Cohort 2, part B subjects: Evaluate overall safety profile of up to 10 treatment cycles of M-CENK and N-803 in subjects with relapsed or refractory (R/R) solid tumors by the number of participants with clinically significant laboratory tests.
Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) and will be performed within 1 calendar day prior to dosing. Vital signs.
Cohort 2, part B subjects: Evaluate the overall safety profile of up to 10 treatment cycles of M CENK and N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of of participants with abnormal vital signs.
- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation
Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the objective response rate (ORR) by the percentage of subjects that achieve a confirmed complete or partial overall response
- ORR will be measured every 8 weeks (± 1 week) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST) and the percentage of subjects that achieve a confirmed complete or partial overall response will be presented. The 95% confidence interval of the response rate will be presented. Response will be assessed using both RECIST and iRECIST.
Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the progression-free survival (PFS) by the
- PFS will be measured every 8 weeks (± 1 week) by RECIST Version 1.1 and iRECIST and will be evaluated using Kaplan-Meier methods. PFS will be defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first.
Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the overall survival (OS) from the first date of treatment to the date of death.
Overall Survival will be evaluated using Kaplan-Meier methods. OS will be defined as the time from the date of first treatment to the date of death (any cause). Subjects who are alive at the end of follow-up will be censored at the last known date alive.

Full Information

First Posted
May 10, 2021
Last Updated
June 26, 2023
Sponsor
ImmunityBio, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04898543
Brief Title
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Official Title
Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 21, 2021 (Actual)
Primary Completion Date
June 21, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ImmunityBio, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic solid tumors. The study consists of two cohorts: cohort 1 includes subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment; and cohort 2 that includes subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies. The two cohorts will be conducted simultaneously.
Detailed Description
The 2 cohorts will be enrolled simultaneously. Both cohorts have a part A (apheresis) and cohort 2 has a part B (M-CENK treatment [one bag has a 100 mL cell suspension containing 0.25 to 0.75 x 109 cells] and N-803 treatment). A dose is a single administration of M-CENK cells or a single administration of N-803. A treatment cycle is defined as M-CENK cells that are infused on study days 1, 8, 15, and 22 in combination with subcutaneous N-803 on days 1 and 15 followed by 1 week with no treatment. In order that 10 subjects who were initially enrolled in cohort 1 and subsequently qualify for cohort 2, receive at least 1 M-CENK treatment cycle, up to 30 subjects may be enrolled in cohort 1. Subjects in cohort 1 will participate in apheresis collection of lymphocytes (part A) prior to receiving disease specific first-line therapy (if they have not received prior therapy) per primary oncologists' recommendations. Subjects in cohort 1 may subsequently enroll in cohort 2 part B while receiving standard of care (SOC) treatment. Thus, subjects who have completed apheresis in cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy. They must also meet the inclusion criteria to participate in the treatment phase (part B). In order that 10 subjects receive at least a single dose of M-CENK, up to 20 subjects may be enrolled in cohort 2. Subjects in cohort 2 will undergo an apheresis collection of lymphocytes (part A) prior to receiving approximately 4 weeks of disease-specific therapy per oncologists' recommendations while the M-CENK cells are being manufactured for use in the treatment phase (part B). Subjects in part A will be re-evaluated for eligibility in inclusion/exclusion criteria prior to enrollment into part B. Prior to study treatment cycle 1, a washout period of 2 weeks is required to receive M-CENK cells and N-803. M-CENK cells, manufactured from the autologous apheresis product, will be infused on study days 1, 8, 15, and 22 in combination with subcutaneous N-803 on days 1 and 15, followed by one week of no treatment. Thus, assuming that sufficient doses of M-CENK are available, each cycle is a 5-week period that includes up to 4 infusions of M-CENK in combination with 2 doses of N-803 and concludes with 1 week of no treatment. In the event that fewer than 4 doses of M-CENK cells are manufactured for a subject, the subject may receive 1 to 3 doses of M-CENK cells in the first treatment cycle. In the event that more than 4 doses of M-CENK are manufactured, the subject may receive the additional cycles of M-CENK cells using the same dosing regimen. The treatment cycle may be completed up to 10 times, if the subject tolerates treatment, the doses of M-CENK cells are available, and the Investigator believes there may be potential benefit to the subject. Safety endpoints include assessments of TEAEs, SAEs, and clinically significant changes in safety laboratory tests, and vital signs. Toxicities will be graded using CTCAE Version 5.0, or in the case of CRS, using a specified grading system. Safety will be monitored throughout the study. The treatment of the initial 3 subjects in cohort 2 part B will be staggered with at least a 2-week interval between each subject. After the first 3 subjects in cohort 2 part B are treated, the treatment of existing subjects in cohort 2 part B will be paused after the 14-day toxicity assessment period for a safety evaluation by the Safety Review Committee (SRC). Based on the SRC safety evaluation, the treatment of the subsequent subjects can proceed if the safety evaluation from the initial 3 subjects in part B suggests that the therapy is safe. There will be another safety review after all subjects in cohort 2 have completed the 14-day toxicity assessment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Solid Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment
Arm Type
Experimental
Arm Description
Cohort 1: Subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment. Cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy and meet the inclusion criteria for cohort 2 part B.
Arm Title
Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors
Arm Type
Experimental
Arm Description
Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies or not a candidate for therapy of proven efficacy for their disease.
Intervention Type
Biological
Intervention Name(s)
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK)
Intervention Description
M-CENK will be administered 4 times via intravenous (IV) infusion on days 1, 8, 15 and 22. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
Intervention Type
Biological
Intervention Name(s)
N803
Intervention Description
N803 15 μg/kg will be administered subcutaneously on days 1 and 15.
Intervention Type
Other
Intervention Name(s)
Apheresis collection of lymphocytes (part A)
Intervention Description
Subjects in cohort 1 will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
Primary Outcome Measure Information:
Title
Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.
Description
- Safety of apheresis collection as indicated by incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, or in the case of cytokine release syndrome (CRS), using the specified grading system.
Time Frame
Study Day 1, assessed for up to 1 week
Title
Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests.
Description
- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to apheresis collection. Hematology test will be performed pre- and post- apheresis collection.
Time Frame
From Baseline/Screening through Study Day 1, assessed for up to 1 day
Title
Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs.
Description
- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation
Time Frame
From Baseline/Screening through Study Day 1, assessed for up to 28 days
Title
Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (treatment cycle 1, Day 1)
Description
- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using the specified grading system.
Time Frame
From Cycle 1 Day 1 up to 30 days, assessed for up to 30 days
Title
Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests
Description
- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to first dose.
Time Frame
From Cycle 1 Day 1 up to 1 day, assessed for up to 1 day
Title
Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs
Description
- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation
Time Frame
From Cycle 1 Day 1 up to 1 day, assessed for up to 1 day
Secondary Outcome Measure Information:
Title
Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs for manufacturing M-CENK cells.
Description
- Number of MNCs for manufacturing M-CENK cells
Time Frame
Study Day 1
Title
Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs collected and the % of natural killer (NK) cells.
Description
Number of MNCs collected and the percentage of natural killer (NK) cells (CD56/CD16 positive) after a 2 blood volume apheresis collection.
Time Frame
Study Day 1
Title
Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells.
Description
- Number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells as measured by flow cytometry and interferon (IFN) γ production, and cytotoxicity following enrichment and expansion of the NK cells ex vivo.
Time Frame
Study Day 1
Title
Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of cryopreserved aliquots of manufactured M-CENK cells.
Description
- Number of cryopreserved aliquots of manufactured M-CENK cells.
Time Frame
Study Day 1
Title
Secondary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of up to 10 treatment cycles of M CENK and N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of TEAEs and SAEs.
Description
- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using a specified grading system.
Time Frame
From Cycle 1 Day 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months
Title
Cohort 2, part B subjects: Evaluate overall safety profile of up to 10 treatment cycles of M-CENK and N-803 in subjects with relapsed or refractory (R/R) solid tumors by the number of participants with clinically significant laboratory tests.
Description
Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) and will be performed within 1 calendar day prior to dosing. Vital signs.
Time Frame
From Cycle 1 Day 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months
Title
Cohort 2, part B subjects: Evaluate the overall safety profile of up to 10 treatment cycles of M CENK and N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of of participants with abnormal vital signs.
Description
- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation
Time Frame
From Cycle 1 Day 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months
Title
Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the objective response rate (ORR) by the percentage of subjects that achieve a confirmed complete or partial overall response
Description
- ORR will be measured every 8 weeks (± 1 week) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST) and the percentage of subjects that achieve a confirmed complete or partial overall response will be presented. The 95% confidence interval of the response rate will be presented. Response will be assessed using both RECIST and iRECIST.
Time Frame
From Baseline/Screening through End of Study (up to 12 months from first dose), measured every 8 weeks
Title
Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the progression-free survival (PFS) by the
Description
- PFS will be measured every 8 weeks (± 1 week) by RECIST Version 1.1 and iRECIST and will be evaluated using Kaplan-Meier methods. PFS will be defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first.
Time Frame
From Cycle 1 Day 1 to the date of disease progression or death (any cause), assessed for up to 12 months
Title
Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the overall survival (OS) from the first date of treatment to the date of death.
Description
Overall Survival will be evaluated using Kaplan-Meier methods. OS will be defined as the time from the date of first treatment to the date of death (any cause). Subjects who are alive at the end of follow-up will be censored at the last known date alive.
Time Frame
From Cycle 1 Day 1 to the date of death (any cause), assessed for up to 12 months
Other Pre-specified Outcome Measures:
Title
Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by frequency and phenotype of immune cells as measured by flow and mass cytometry..
Description
- Frequency and phenotype of immune cells as measured by flow and mass cytometry.
Time Frame
From Baseline/Screening through Study Day 1
Title
Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by frequency, number, phenotype, and proliferation of NK cells as measured by flow and mass cytometry.
Description
- Frequency, number, phenotype, and proliferation of NK cells as measured by flow and mass cytometry. Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. - Serum cytokines.
Time Frame
From Baseline/Screening through Study Day 1
Title
Cohort 1/2, part A subjects: Evaluate and compare immune profiles of whole blood and apheresis product by function of NK cells and NK cell receptor profile by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity.
Description
Exploratory Objective: Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. Serum cytokines.
Time Frame
From Baseline/Screening through Study Day 1
Title
Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by measuring serum cytokines.
Description
- Serum cytokines.
Time Frame
From Baseline/Screening through Study Day 1
Title
Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by frequency and phenotype of immune cells as measured by flow and mass cytometry.
Description
- Frequency and phenotype of immune cells as measured by flow and mass cytometry.
Time Frame
From Baseline/Screening through End of Study, assessed for up to 12 months
Title
Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity.
Description
- Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity.
Time Frame
From Baseline/Screening through End of Study, assessed for up to 12 months
Title
Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by measuring serum cytokines.
Description
- Serum cytokines.
Time Frame
From Baseline/Screening through End of Study, assessed for up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines. Have histologically confirmed locally advanced, unresectable, or metastatic solid tumor. For subjects with genetic mutations or alterations in solid tumors (e.g. NSCLC, pancreatic cancer, melanoma), the subjects must have received prior appropriate disease specific targeted therapy and have progressed. Have at least 1 measurable lesion and/or non-measurable disease evaluable in accordance with RECIST Version 1.1. For subjects with genetic mutations or alterations in solid tumors (eg, non-small cell lung cancer, pancreatic cancer, melanoma), the subjects must have received prior appropriate disease-specific targeted therapy and have progressed. For subjects with a history of human immunodeficiency virus (HIV) Subjects with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL and without a history of AIDS defining opportunistic infections are eligible. For subjects with a history of hepatitis B virus (HBV) Subjects who are chronic carriers of HBV infection (HBsAg-positive, undetectable or low HBV DNA, and normal ALT) who are not on HBV therapy, or in individuals who have serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and anti-HBc-positive), anti-HBV prophylaxis should be assessed prior to enrollment. Subjects with chronic HBV infection with active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy prior to enrollment. For subjects with a history of hepatitis C virus (HCV) Subjects with a history of HCV infection should have completed curative antiviral treatment and have a HCV viral load below the limit of quantification are eligible. Subjects who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Subjects on concurrent HCV treatment and have HCV below the limit of quantification are eligible. Note: Subjects who have a history of HIV/HBV/HCV or are seropositive will require Infectious Disease Marker (IDM) testing prior to apheresis collection. Subjects who currently have non-progressive brain metastasis and were previously treated with surgical resection/debulking, radiation, and stereotactic radiosurgery. Able to undergo an Apheresis procedure: Have adequate venous access Able to sit or recline for 5-6 hours with limited movement Hemoglobin must be ≥ 9.0 g/dL Platelet count must be ≥ 100,000 cells/mm3 Vital signs must be within normal range Negative serum pregnancy test for females of childbearing potential. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Cohort 2 subjects only: Have documented progressive disease after receiving treatment with at least 2 prior lines of therapy or not be a candidate for therapy of proven efficacy for their disease. Prior immune therapy and prior treatment with a checkpoint inhibitor as per FDA indication for current standard of care therapy are allowed. Have completed a 2-week washout period following treatment with an approved chemotherapy or approved immunotherapy prior to receiving the investigational products. A repeat lab of at least 14 days after completion of the treatment to demonstrate recovery of counts to an ANC ≥ 1000, platelets ≥100,000 cells/mm3, albumin ≥ 3 g/dL, and AST/ALT within normal limits are required. The AST/ALT must be < 2.5 ULN in subjects with liver metastases. Have completed a 2-week washout period following treatment with an investigational chemotherapy or investigational immunotherapy prior to receiving the investigational products. A repeat lab of at least 30 days after completion of the treatment to demonstrate recovery of counts to an ANC ≥ 1000, platelets ≥ 100,000 cells/mm3, albumin ≥ 3 g/dL, and AST/ALT within normal limits are required. The AST/ALT must be < 2.5 ULN in subjects with liver metastases. Ability to attend required study visits and return for adequate follow-up, as required by this protocol. Agreement to practice effective contraception for female subjects of child-bearing potential and nonsterile males. Exclusion Criteria (Cohort 1 part A): There is no exclusion criteria for Cohort 1 part A. Exclusion Criteria (Cohort 2 part B only): Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment- related complications. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma) requiring medical treatment Currently receiving or has received antibiotics within the last 30 days. History of organ transplant requiring immunosuppression. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), unless the inflammation is well controlled. Inadequate organ function, evidenced by the following laboratory results: Absolute neutrophil count (ANC) < 1000 cells/mm3. Platelet count < 100,000 cells/mm3. Hemoglobin < 9 g/dL. Total bilirubin > 1.5 x the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome). AST (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases). Alkaline phosphatase (ALP) levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases). Serum creatinine > 2.0 mg/dL or 177 μmol/L. Note: Each site should use its own institution's upper limit of normal (ULN) to determine eligibility. Subjects with ascites requiring paracentesis or pleural effusion requiring thoracentesis. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. Oxygen therapy on an as needed or intermittent basis is allowed. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. Known hypersensitivity to any component of the study medication(s). Participation in an investigational drug study or history of receiving any investigational treatment or cytotoxic chemotherapy within 14 days prior to dosing for this study, except for testosterone-lowering therapy in men with prostate cancer or anti-estrogen therapy for women with breast cancer. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol. Concurrent participation in any interventional clinical trial. Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 24 hours prior to the first dose must be documented before M-CENK is administered to a female subject of childbearing potential.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lauren Wilkins
Phone
310-882-9593
Email
lauren.wilkins@immunitybio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jayson Garmizo
Phone
310-912-2230
Email
jayson.garmizo@immunitybio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leonard Sender, MD
Organizational Affiliation
ImmunityBio, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Chan Soon-Shiong Institute for Medicine
City
El Segundo
State/Province
California
ZIP/Postal Code
90245
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacqui Parnin
Phone
213-266-5604
Email
Jacqui.Parnin@cssifm.org
First Name & Middle Initial & Last Name & Degree
Chaitali Nangia, MD
Facility Name
Hoag Memorial Hospital Presbyterian
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leila Andres
Phone
949-764-8092
Email
leila.andres@hoag.org
First Name & Middle Initial & Last Name & Degree
Tara E Seery, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs